Clinical Trial Update: Paraclinical Cardiometabolic Risk Assessment in Type 2 Diabetes

View source ↗

Summary

A completed clinical trial evaluating paraclinical cardiometabolic risk assessment in people with type 2 diabetes and dyslipidemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Type 2 Diabetes Mellitus

Snippet

Sponsor: Tokat Gaziosmanpasa University | Conditions: Dyslipidemia Associated With Type II Diabetes Mellitus | Status: COMPLETED